Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Veterinary Molecular Diagnostics Market Size & Share 2026-2035
Report ID: GMI6325
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Veterinary Molecular Diagnostics Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Veterinary Molecular Diagnostics Market Size
The veterinary molecular diagnostics market was valued at USD 700 million in 2025, is projected to reach USD 770 million in 2026, and is expected to expand at an 8.2% CAGR (2026–2035) to USD 1.53 billion by 2035.
Veterinary Molecular Diagnostics Market Key Takeaways
Market Leader: IDEXX Laboratories led with over 30.7% market share in 2025.
Leading Players: Top 5 players in this market include IDEXX Laboratories, Antech Diagnostics, Thermo Fisher Scientific, Zoetis, QIAGEN, which collectively held a market share of 48.8% in 2025.
Veterinary molecular diagnostics market growth reflects the wider incorporation of nucleic acid testing into routine companion-animal care, livestock biosecurity, and public-health surveillance. PCR remains central to validated infectious-disease workflows, while sequencing and isothermal platforms expand testing into genetic screening, oncology, and time-sensitive field use.
GMI Analyst View
Our discussions with veterinary diagnostics market participants and reference laboratory operators indicate the market is on pace to surpass USD 848 million in annual revenues by 2027, reflecting a front-loaded growth profile driven by laboratory instrument upgrade cycles, expanding PCR assay menus, and accelerating uptake of genetic testing among companion animal practitioners in North America and Western Europe. This near-term trajectory underscores the structural rather than cyclical nature of current demand growth.
Veterinary Molecular Diagnostics Market Trends, Growth Drivers & GMI Forecast Outlook
Companion-animal healthcare spending, outbreak surveillance, and increasingly deployable molecular platforms are expanding the addressable testing base. The outlook nevertheless depends on whether laboratories and care providers can contain workflow complexity, sustain trained staffing, and translate technical capability into affordable clinic-level services.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Companion-animal care is becoming more diagnosis-led as practices face greater demand for confirmation before treatment and for actionable differentiation among pathogens with similar presentations. This changes molecular testing from an exceptional referral service into a repeatable part of respiratory, gastrointestinal, vector-borne, hereditary, and oncology workups. Reference laboratories are positioned to capture much of this volume because they can support broad menus, quality systems, and specialist interpretation.
Disease-control procurement creates a separate demand mechanism. Molecular surveillance is not solely a response to individual outbreaks; it also establishes assay validation, laboratory capacity, and sample-routing routines that remain useful after the immediate event. That installed capability supports recurring livestock, poultry, food-safety, and zoonotic monitoring work, giving molecular testing a more resilient institutional demand base than discretionary diagnostic categories.
Compact amplification formats widen the practical settings in which molecular results can influence care. In-clinic and field deployment can reduce the operational cost of delayed diagnosis, but adoption will depend on closed workflows, meaningful menu breadth, dependable quality control, and results that clinicians can incorporate without adding excessive staff burden.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Molecular testing must compete with lower-cost immunoassays, empiric treatment, and delayed referral in settings where diagnostic spending is discretionary. The economic hurdle is especially material when an assay's clinical value is not obvious to the pet owner at the point of care. Suppliers that pair targeted panels with simple sample logistics and predictable turnaround can improve adoption without requiring every practice to build a molecular laboratory.
Workforce scarcity makes distributed testing harder than instrument specifications alone suggest. Sample preparation, contamination control, exception handling, and interpretation still require trained oversight even where platforms automate amplification. Centralized laboratories therefore retain an operational advantage, while point-of-care vendors must reduce workflow friction rather than merely miniaturize the technology.
Regulatory fragmentation also raises the cost and timing risk of international launches. Assay developers must align validation packages, claims, and commercial sequencing with jurisdiction-specific pathways, which can delay menu expansion and favor established suppliers with regulatory infrastructure.
GMI Analyst View
We view the market's central commercial tension as the gap between high clinical interest in molecular confirmation and the operational capacity required to provide it consistently. The companies most likely to widen adoption will combine economical test formats with workflows that reduce training, referral, and interpretation burdens rather than treating those constraints as secondary implementation issues.
Veterinary Molecular Diagnostics Market Segment Analysis
By Product
Kits & Reagents generated USD 455 million in 2025 and are projected to reach USD 982 million by 2035. Their position reflects the recurring consumables requirement of extraction, amplification, sequencing preparation, and validated assay workflows, making test-volume growth directly relevant to replenishment demand.
Instruments are expected to account for 36.0% of the market in 2035 and advance at an 8.5% CAGR (2026–2035). Upgrade cycles are shifting demand toward multiplex, digital, and compact systems, while first-time installations remain important where veterinary laboratory capacity is still being built.
By Technology
PCR generated USD 434 million in 2025 and is expected to account for 52.0% of the market in 2035. Its installed base, validated menus, and laboratory familiarity preserve its role as the core platform for infectious-disease confirmation and surveillance, even as adjacent technologies take incremental use cases.
Sequencing/NGS is projected to reach USD 368 million by 2035 and expand at a 15.0% CAGR (2026–2035). Its growing relevance rests on applications in pathogen characterization, oncology profiling, and genetic disease analysis, although bioinformatics capability remains a practical constraint on broad routine adoption [5]MDPI Animals. "Application of Next-Generation Sequencing (NGS) Techniques for Selected Companion Animals." mdpi.com.
INAAT generated USD 84 million in 2025 and is projected to represent 15.0% of the market in 2035. The technology's lower infrastructure requirements support its use in clinics, farms, shelters, and field environments where conventional thermocycler workflows are impractical.
Microarray platforms accounted for 8.0% of the market in 2025 and are projected to generate USD 107 million by 2035. They retain a specialist role in hereditary screening, livestock genomics, and pharmacogenomic applications, but centralized processing requirements limit their reach relative to more deployable molecular formats.
Other technologies represented 5.0% of the market in 2025 and are forecast to decline at a -1.2% CAGR (2026–2035). Legacy formats face displacement as laboratories seek greater analytical sensitivity, menu flexibility, and scalable throughput.
By Application
Infectious Disease Diagnostics generated USD 385 million in 2025 and are projected to reach USD 828 million by 2035. Recurring demand is anchored in pathogen confirmation, outbreak response, and government surveillance, with multiplex panels supporting both companion-animal care and livestock biosecurity.
Genetic/Genomic Testing accounted for 30.0% of the market in 2025 and is expected to grow at an 8.9% CAGR (2026–2035). Hereditary-risk screening, parentage, pharmacogenomics, and oncology testing broaden the category beyond acute illness, creating an adoption pathway tied to preventive care and breed-management decisions.
Other applications represented 15.0% of the market in 2025 and are projected to generate USD 215 million by 2035. Antimicrobial-resistance monitoring, food-safety testing, wildlife surveillance, and research-adjacent work provide a policy- and program-supported demand base that complements clinical diagnostics.
By Animal Type
Companion Animals generated USD 364 million in 2025 and are projected to reach USD 844 million by 2035. Higher diagnostic intensity, demand for rapid clinical decisions, and expanding genetic and oncology test menus support a more value-oriented testing mix in this segment.
Livestock/Food Animal diagnostics accounted for 48.0% of the market in 2025 and are expected to advance at a 7.5% CAGR (2026–2035). High-volume surveillance, export requirements, and farm biosecurity sustain demand, although the segment's lower per-test economics moderate revenue expansion relative to companion-animal testing.
By End Use
Reference/Commercial Laboratories generated USD 315 million in 2025 and are projected to account for 42.0% of the market in 2035. Their centralized automation, specialist staffing, and procurement scale support broad assay menus and make them the principal channel for complex and high-throughput molecular work.
Veterinary Hospitals represented 25.0% of the market in 2025 and are projected to generate USD 399 million by 2035. Specialty and emergency settings are increasingly suitable for mid-throughput systems where molecular confirmation can affect immediate treatment, isolation, or surgical decisions.
Veterinary Clinics generated USD 140 million in 2025 and are expected to expand at an 8.7% CAGR (2026–2035). Adoption depends on compact systems that fit a single-visit workflow and minimize operator burden while offering panels relevant to common companion-animal presentations.
Other end users are projected to generate USD 169 million by 2035 and represented 10.0% of the market in 2025. Government agencies, academic institutions, wildlife programs, and field units provide demand linked to disease-control mandates, research funding, and national animal-health infrastructure.
GMI Analyst View
We see the segment transition as additive rather than replacement-driven. PCR's installed base remains commercially consequential, while sequencing and isothermal methods address different workflow and information needs. The most durable growth opportunities sit where platform design matches the operating reality of the end user, particularly where faster access does not compromise diagnostic confidence.
Veterinary Molecular Diagnostics Market Regional Analysis
North America Veterinary Molecular Diagnostics Market Analysis
North America generated USD 294 million in 2025 and is projected to reach USD 628 million by 2035. The veterinary molecular diagnostics market in the region benefits from established reference-laboratory networks, sophisticated companion-animal care, and institutional demand for livestock and zoonotic-disease surveillance.
US
The US generated USD 256 million in 2025 and is projected to account for 85.4% of North American revenues in 2035. National laboratory infrastructure and commercial referral networks create a strong foundation for high-throughput molecular testing across both companion-animal and food-animal workflows.
Canada
Canada accounted for 12.9% of North American revenues in 2025 and is expected to advance at a 9.2% CAGR (2026–2035). Companion-animal care in metropolitan markets and biosecurity investment in poultry and livestock support a growing molecular-testing base.
Europe Veterinary Molecular Diagnostics Market Analysis
Europe generated USD 196 million in 2025 and is projected to reach USD 430 million by 2035. The region's veterinary molecular diagnostics market is supported by established diagnostic infrastructure, animal-health regulation, and demand for companion-animal and livestock testing.
Germany
Germany generated USD 42 million in 2025 and is projected to reach USD 89 million by 2035. Its combination of commercial livestock activity, companion-animal demand, and specialized laboratory capacity makes it an important European market for molecular workflows.
UK
The UK represented 18.4% of European revenues in 2025 and is expected to grow at an 8.6% CAGR (2026–2035). Demand is underpinned by an established companion-animal care culture and laboratory-supported food-animal surveillance.
France
France generated USD 28 million in 2025 and is projected to account for 14.0% of European revenues in 2035. Poultry and cattle surveillance complement urban companion-animal testing, producing a mixed source of demand for laboratories and assay suppliers.
Italy
Italy accounted for 11.2% of European revenues in 2025 and is projected to generate USD 46 million by 2035. Regional laboratory networks and livestock surveillance needs support molecular diagnostics alongside expanding companion-animal demand in urban areas.
Spain
Spain generated USD 18 million in 2025 and is expected to advance at a 7.2% CAGR (2026–2035). Its substantial pork and poultry industries provide a livestock-testing foundation, while companion-animal diagnostics create an additional clinic-referral opportunity.
Netherlands
The Netherlands accounted for 7.1% of European revenues in 2025 and is projected to generate USD 29 million by 2035. Specialized veterinary capability and poultry-dense production areas support sustained laboratory demand despite the country's comparatively compact market base.
Asia Pacific Veterinary Molecular Diagnostics Market Analysis
Asia Pacific generated USD 154 million in 2025 and is projected to account for 25.0% of the global market in 2035. The veterinary molecular diagnostics market is expanding through urban companion-animal care, large-scale livestock biosecurity programs, and investment in national laboratory networks.
China
China generated USD 52 million in 2025 and is expected to grow at a 10.6% CAGR (2026–2035). Commercial swine and poultry production, surveillance requirements, and a growing urban pet-care economy create multiple channels for molecular test demand.
India
India is projected to generate USD 63 million by 2035 and advance at a 12.2% CAGR (2026–2035). Increasing laboratory modernization, livestock disease-control programs, and a developing companion-animal market create a broad runway from comparatively low molecular-test penetration.
Japan
Japan represented 19.5% of Asia Pacific revenues in 2025 and is projected to generate USD 62 million by 2035. Mature companion-animal care and established veterinary laboratory infrastructure support routine use of molecular infectious-disease testing.
Australia
Australia generated USD 18 million in 2025 and is projected to account for 10.2% of Asia Pacific revenues in 2035. Biosecurity priorities and companion-animal testing demand support adoption, particularly where molecular confirmation is integral to exotic-disease preparedness.
South Korea
South Korea represented 11.7% of Asia Pacific revenues in 2025 and is expected to grow at a 9.8% CAGR (2026–2035). Companion-animal demand, domestic diagnostic suppliers, and poultry surveillance programs collectively support market development.
Latin America Veterinary Molecular Diagnostics Market Analysis
Latin America generated USD 35 million in 2025 and is projected to reach USD 61 million by 2035. The veterinary molecular diagnostics market is led by urban companion-animal demand and export-linked livestock testing, although infrastructure and affordability constraints favor centralized laboratory models.
Brazil
Brazil represented 48.6% of Latin American revenues in 2025 and is projected to generate USD 28 million by 2035. Its livestock-export position supports institutional molecular testing, while larger cities offer a growing commercial base for companion-animal diagnostics.
Mexico
Mexico generated USD 7 million in 2025 and is expected to expand at a 6.4% CAGR (2026–2035). Urban pet ownership and surveillance demand from poultry and swine operations support gradual market development.
Middle East and Africa Veterinary Molecular Diagnostics Market Analysis
Middle East and Africa generated USD 21 million in 2025 and is projected to reach USD 31 million by 2035. Government food-safety investment and selected urban companion-animal markets support adoption, while infrastructure gaps limit broad clinic-level penetration across much of the region.
UAE
The UAE accounted for 28.6% of Middle East and Africa revenues in 2025 and is projected to generate USD 10 million by 2035. Integrated biosecurity programs and concentrated companion-animal services underpin molecular-testing demand in government and commercial laboratories.
Saudi Arabia
Saudi Arabia generated USD 5 million in 2025 and is expected to advance at a 4.8% CAGR (2026–2035). Food-animal biosecurity investment, particularly in dairy and poultry, remains the principal driver of molecular adoption.
South Africa
South Africa accounted for 23.8% of Middle East and Africa revenues in 2025 and is expected to grow at a 3.4% CAGR (2026–2035). Its role as a regional veterinary laboratory hub supports service demand, although economic pressure constrains more discretionary testing.
GMI Analyst View
We expect regional performance to remain defined by the interaction of laboratory maturity, public-sector surveillance, and companion-animal care intensity. Asia Pacific offers the clearest expansion opportunity, while North America and Europe continue to provide the deepest installed base and the most predictable demand for high-complexity testing.
Veterinary Molecular Diagnostics Market Share & Competitive Landscape
The veterinary molecular diagnostics market exhibits a moderately concentrated competitive structure, with IDEXX Laboratories, Antech Diagnostics, Thermo Fisher Scientific, Zoetis, and QIAGEN collectively accounting for approximately 48.8% of global market revenue in 2025. Market competition is driven by the breadth of diagnostic test menus, laboratory network coverage, assay validation capabilities, turnaround time, and integration with veterinary clinical workflows. Leading companies benefit from established reference laboratory infrastructure, strong relationships with veterinary practices, and extensive molecular testing capabilities, while specialized providers compete through niche assay offerings, pathogen-specific expertise, and regional market presence.
Other notable participants include Neogen Corporation, Bio-Rad Laboratories, Heska Corporation, bioMérieux, INDICAL BIOSCIENCE, Bioneer Corporation, BIONOTE, Agrolabo, Innovative Diagnostics, and GZ MED, which compete through specialized offerings in pathogen detection, genomics, molecular reagents, extraction technologies, field diagnostics, and livestock disease testing. As veterinary healthcare providers increasingly adopt advanced molecular diagnostics, competition is becoming increasingly focused on assay accuracy, workflow efficiency, laboratory service capabilities, and the ability to support emerging animal health surveillance and disease management requirements.
Recent Industry Developments
In January 2025, IDEXX Laboratories launched IDEXX Cancer Dx as a blood-based molecular diagnostic panel for early canine lymphoma detection through its veterinary reference laboratory service [3]IDEXX Laboratories. "IDEXX Announces Groundbreaking Cancer Dx Panel with Affordable Early Detection Test for Canine Lymphoma." idexx.com. The launch illustrates how oncology testing may broaden molecular diagnostics beyond acute infectious-disease workflows and increase the role of preventive companion-animal screening.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →